Alzheimer Disease
1,759
315
410
870
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
260 trials with published results (15%)
Research Maturity
870 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.8%
120 terminated out of 1759 trials
87.9%
+1.3% vs benchmark
8%
149 trials in Phase 3/4
30%
260 of 870 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 870 completed trials
Clinical Trials (1759)
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
Improving Sleep and Cognition in Alzheimer's Disease
Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease
Clinical Trial on Agitation in Alzheimer's Dementia
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Alzheimer's Disease Neuroimaging Initiative 4
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
The Gut - PRO Study
Indian Transforming Alzheimer's Care Training (INTACT)
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Improving PCP Advance Care Planning for People With ADRD
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
A Study of LY3439539 in Participants With Alzheimer's Disease
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease